[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 4 of about 4
1. Benjamin RS, Patel SR: Pediatric and adult osteosarcoma: comparisons and contrasts in presentation and therapy. Cancer Treat Res; 2009;152:355-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pediatric and adult osteosarcoma: comparisons and contrasts in presentation and therapy.
  • Most data on osteosarcoma is derived from pediatric studies.
  • Although the majority of adult patients with osteosarcoma are young adults, who might be treated in a similar fashion, experience derived from a slightly older population is helpful in directing therapy.
  • We treated a series of 123 patients with osteosarcoma of the extremities with adriamycin and cisplatin as induction therapy.
  • Sequential addition of methotrexate and methotrexate plus ifosfamide in subsequent cohorts improved the continuous relapse-free survival of poor responders such that overall survival improvement was noted in the group where therapy was modified by adding both agents to those with <90% tumor necrosis.
  • Patients with chondroblastic osteosarcoma with poor necrosis had a trend towards improved continuous relapse-free survival compared with other patients with conventional osteosarcoma.
  • Histologic variants of osteosarcoma except telangiectatic osteosarcoma had a worse prognosis than those with conventional osteosarcoma.
  • The variants, especially dedifferentiated parosteal osteosarcoma and dedifferentiated well-differentiated intraosseous osteosarcoma are more common in adults than children, accounting for some of the inferior prognosis in adults.
  • Patients with secondary osteosarcoma are often much older as are many with osteosarcomas of the pelvis and jaw.
  • An attempt to intensify therapy in poor-prognosis patients with a three-drug regimen of adriamycin, cisplatin, and ifosfamide with peripheral stem cell support was unsuccessful at prolonging relapse-free survival, and we no longer use that approach.
  • [MeSH-major] Bone Neoplasms / drug therapy. Osteosarcoma / drug therapy

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20213401.001).
  • [ISSN] 0927-3042
  • [Journal-full-title] Cancer treatment and research
  • [ISO-abbreviation] Cancer Treat. Res.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


2. Newkirk L, Vater Y, Oxorn D, Mulligan M, Conrad E: Intraoperative TEE for the management of pulmonary tumour embolism during chondroblastic osteosarcoma resection. Can J Anaesth; 2003 Nov;50(9):886-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraoperative TEE for the management of pulmonary tumour embolism during chondroblastic osteosarcoma resection.
  • PURPOSE: Chondroblastic osteosarcoma requiring surgical intervention is associated with a high risk of pulmonary tumour embolism.
  • The hemipelvectomy was completed on the next day after fluid and inotropic agent resuscitation.
  • [MeSH-major] Bone Neoplasms / surgery. Chondroblastoma / surgery. Echocardiography, Transesophageal. Monitoring, Intraoperative / methods. Neoplastic Cells, Circulating. Osteosarcoma / surgery. Pulmonary Artery / ultrasonography


3. Hoenerhoff MJ, Kiupel M, Rosenstein D, Pool RR: Multipotential osteosarcoma with various mesenchymal differentiations in a young dog. Vet Pathol; 2004 May;41(3):264-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multipotential osteosarcoma with various mesenchymal differentiations in a young dog.
  • Microscopically, the neoplasm exhibited osteosarcomatous, chondrosarcomatous, liposarcomatous, leiomyosarcomatous, fibrosarcomatous, angiosarcomatous, and leukocytic differentiation and was diagnosed as a multipotential osteosarcoma with various mesenchymal differentiation.
  • Skeletal metastases from a primary bone tumor are exceedingly rare in human and veterinary medicine.
  • In addition, the wide range of mesenchymal tissue differentiation of this neoplasm was unusual, and to the authors' knowledge, an osteosarcoma with this degree of multiple differentiation has not been previously reported in the dog.
  • [MeSH-major] Bone Neoplasms / veterinary. Dog Diseases / pathology. Osteosarcoma / veterinary
  • [MeSH-minor] Animals. Dogs. Immunohistochemistry. Kidney Neoplasms / secondary. Kidney Neoplasms / veterinary. Liver Neoplasms / secondary. Liver Neoplasms / veterinary. Male. Neoplasm Invasiveness. Splenic Neoplasms / secondary. Splenic Neoplasms / veterinary

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15133175.001).
  • [ISSN] 0300-9858
  • [Journal-full-title] Veterinary pathology
  • [ISO-abbreviation] Vet. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


Advertisement
4. Jäger M, Schultheis A, Westhoff B, Krauspe R: Osteogenic progenitor cell potency after high-dose chemotherapy (COSS-96). Anticancer Res; 2005 Mar-Apr;25(2A):947-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Osteogenic progenitor cell potency after high-dose chemotherapy (COSS-96).
  • BACKGROUND: Since the first trial of chemotherapy in patients with osteosarcoma the survival rate has gradually improved.
  • For more than two decades, most osteosarcoma patients from Germany, Austria and Switzerland have been treated according to the protocols of the Cooperative Osteosarcoma Study Group (COSS).
  • PATIENTS AND METHODS: In this study the osteogenic stem cell potency of three different tissue types was elucidated after COSS-96 chemotherapy (high-risk arm).
  • Mononuclear cells were obtained from the periosteum, cartilage and bone marrow of a 17-year-old female with a chondroblastic osteosarcoma.
  • The cells were cultivated for 4 weeks in standard medium and stimulated for osteogenic differentiation after the second passage with dexamethasone, glycerolphosphate and ascorbine acid.
  • CONCLUSION: The results of this study demonstrate the survival of mesenchymal progenitor cells in bone marrow during COSS-96 polychemotherapy, which allows for an osteogenic regeneration in vitro and potentially in vivo.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Bone Neoplasms / pathology. Mesenchymal Stromal Cells / cytology. Mesenchymal Stromal Cells / drug effects. Osteosarcoma / drug therapy. Osteosarcoma / pathology
  • [MeSH-minor] Adolescent. Bone Marrow Cells / cytology. Bone Marrow Cells / drug effects. Cartilage / cytology. Cartilage / drug effects. Cell Differentiation / drug effects. Cell Survival / drug effects. Chondroblastoma / drug therapy. Chondroblastoma / pathology. Cisplatin / administration & dosage. Cisplatin / adverse effects. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Methotrexate / administration & dosage. Methotrexate / adverse effects. Neoadjuvant Therapy. Periosteum / cytology. Periosteum / drug effects

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868932.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down






Advertisement